Nasus Pharma Ltd
Nasus Pharma Ltd (NSRX): 9 pipeline candidates · 3 upcoming catalysts · ~2 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
1.5 months
D/E 0.81 · 0% dilution
Lead: Phase 1/Phase 2
9 candidates
3 upcoming, next in ~24d
2 buys · 0 sells (180d)
A transparent, data-derived signal for Nasus Pharma Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$33.7M
Cash
$1.3M
Quarterly Burn
$4.9M
Runway
1.5 mo
Revenue
$1.2B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| a | Phase 1/Phase 2 |
| b | Phase 1/Phase 2 |
| c | Phase 1/Phase 2 |
| epinephrine autoinjector double dose | Phase 1/Phase 2 |
| epinephrine autoinjector single dose | Phase 1/Phase 2 |
| fmxin002 double dose | Phase 1/Phase 2 |
| fmxin002 double dose + nac | Phase 1/Phase 2 |
| fmxin002 single dose | Phase 1/Phase 2 |
| fmxin002 single dose + nac | Phase 1/Phase 2 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$2.3M
| Holder | Shares | Value |
|---|---|---|
| balyasny asset management l.p. | 898,473 | $2.0M |
| hudson bay capital management lp | 134,771 | $299K |
| morgan stanley | 2,000 | $4K |
| hrt financial lp | 38,897 | $86 |
Frequently asked questions
How many drug candidates are in Nasus Pharma Ltd's pipeline?
Nasus Pharma Ltd (NSRX) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nasus Pharma Ltd's lead drug candidate?
Nasus Pharma Ltd's most advanced tracked candidate is a (Phase 1/Phase 2) for Anaphylaxis.
What is Nasus Pharma Ltd's next catalyst?
Nasus Pharma Ltd's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic R" — expected July 12, 2026.
What is Nasus Pharma Ltd's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nasus Pharma Ltd has approximately 1.5 months of cash runway.
What is Nasus Pharma Ltd's market capitalization?
Nasus Pharma Ltd's market capitalization is approximately $33.7M.
Get the full picture on Nasus Pharma Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.